Mayo Clinic launched two new tech venture companies designed to harness artificial intelligence (AI) and medical algorithms and create “software as medical devices” that clinicians can use to improve treatment across different diseases. 

Centessa, based in Cambridge, Mass. and London, launched as a “novel asset-centric pharmaceutical company.”

Two new companies backed by significant financing that will be used to develop treatments for a wide range of diseases launched: Metagenomi will concentrate on next-generation gene therapies and Kira Pharmaceuticals will tackle complement-mediated diseases.

W2O announced the creation of Hū, the first-of-its kind Patient Activation Organization (PAO).

Ohio-based startup Forge Biologics closed a $40 million Series A financing round that will be used to expand manufacturing capabilities and support the clinical development of a gene therapy program for rare diseases, including the typically fatal Krabbe disease.

Baltimore-based AsclepiX Therapeutics closed a $35 million Series A financing.

Denmark-based Saniona, which is focused on treating eating disorders and diseases of the central nervous system, co-founded a new company that is taking aim at the migraine market.

Drug development accelerator BioMotiv and Bristol-Myers Squibb jointly launched Anteros Pharmaceuticals, which will focus on developing a new class of medicines for fibrotic and inflammatory diseases.

Microsoft announced AI for Health, a new $40 million program which is part of the AI for Good initiative that will leverage artificial intelligence technology to “empower researchers and organizations addressing some of the world’s toughest challenges in health.”

Roivant Sciences – helmed by biotech billionaire Vivek Ramaswamy – launched a new subsidiary, Lokavant, a technology company with the important mission of ensuring that no clinical trial fails due to operational error.